SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Fresh Tracks Therapeutics, Inc. (FRTX) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — FRTX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.69
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.96
Book Value / Share$0.00
Revenue / Share$1.35
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-585.11 |
$15.22M |
$-16.49M |
-108.4% |
| 2015 |
$-317.17 |
$20.95M |
$-9.24M |
-44.1% |
| 2016 |
$-282.12 |
$14.53M |
$-8.97M |
-61.8% |
| 2017 |
$-316.76 |
$13.82M |
$-12.96M |
-93.8% |
| 2018 |
$-234.41 |
$1.62M |
$-16.25M |
-1002.1% |
| 2019 |
$-386.21 |
$7.92M |
$-25.95M |
-327.7% |
| 2020 |
$-38.37 |
$1.82M |
$-20.9M |
-1147.3% |
| 2021 |
$-22.14 |
$404K |
$-39.52M |
-9782.4% |
| 2022 |
$-7.36 |
$6.94M |
$-20.66M |
-297.6% |
| 2023 |
$-0.96 |
$8.01M |
$-5.69M |
-71.1% |
